About the Study

Solid and CNS Tumors: A study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors

This study is for: • Patients who are either older than or equal to 1 year old • Who have been diagnosed a tumor that is SMARCB1 (INI1) or SMARCA4 deficient that has relapsed (has come back) or is refractory (has not responded to earlier treatment) • The specific types of tumors for this study include: - Renal medullary carcinoma - Malignant rhabdoid tumor (extra-CNS) - Atypical teratoid rhabdoid tumor (CNS) - Poorly differentiated chordoma - Epithelioid sarcoma - Other SMARCB1 or SMARCA4 deficient tumors The goal of this study is to find what effects, good and/or bad, the drugs tiragolumab and atezolizumab have on patients with relapsed or refractory solid or CNS tumors. Note: Children's Mercy is not participating in Part A of this study.

Interested in learning more?

Full Study Name: PEPN2121